Stay updated on KarXT for Schizophrenia: Long-term Clinical Trial
Sign up to get notified when there's something new on the KarXT for Schizophrenia: Long-term Clinical Trial page.

Latest updates to the KarXT for Schizophrenia: Long-term Clinical Trial page
- Check6 days agoChange DetectedThe core study condition label 'Schizophrenia' has been removed from the study details. The related topics header and the MedlinePlus Genetics link have also been deleted, reducing related information on the page.SummaryDifference0.1%

- Check14 days agoChange DetectedThe page now indicates that recruitment is closed and adds new help sections for reading the study record and joining a study; there are also minor formatting changes to the Intervention/Treatment label and a revision update to version 3.6.0.SummaryDifference0.2%

- Check21 days agoChange DetectedRevision tag updated to v3.5.5; references to Schizophrenia, related topics:, MedlinePlus Genetics, and the previous Revision: v3.5.4 were removed from the page metadata.SummaryDifference0.1%

- Check28 days agoChange DetectedRelated topic links were added to the page for 'Schizophrenia' and 'MedlinePlus Genetics', expanding cross-links to the condition and a genetics resource. These changes enhance navigation and contextual connections without modifying the study data.SummaryDifference0.1%

- Check42 days agoChange DetectedAdded a new page revision tag: Revision: v3.5.4. The related topics section was updated to remove Schizophrenia and MedlinePlus Genetics, along with the older Revision: v3.5.3 label.SummaryDifference0.1%

- Check49 days agoChange DetectedNew topic tags were added to the study record: Schizophrenia and related topics including MedlinePlus Genetics. This enhances tagging and links to related consumer health information.SummaryDifference0.1%

Stay in the know with updates to KarXT for Schizophrenia: Long-term Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KarXT for Schizophrenia: Long-term Clinical Trial page.